withdrawal of the AED. Although occurrence of idiosyncratic adverse effects can only rarely be predicted or prevented, there are known risk factors that can help in identifying patients at high risk. Occurrence of an idiosyncratic event in a close relative, a concomitant autoimmune disease, co-treatment with specific drugs, history of a previous allergic drug reaction, starting treatment with high doses and rapid titration have all been associated with a higher risk of idiosyncratic adverse effects.
New AEDs have been developed in the last two decades with the aim of improving the benefit-risk balance of AED therapy. Available evidence suggests that the newer AEDs are no more effective but may be somewhat better tolerated than older molecules.
We performed a literature review with the aim of evaluating safety and tolerability of second-and third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom secondand third-generation AEDs were administered.
Antiepileptic drugs (AEDs) have been considered amongst the drugs most frequently associated with fatal suspected adverse drug reactions in a UK study. [1] As every AED has potential adverse effects, indications for introducing a new molecule in the treatment regimen should be carefully weighed with the objective of improving seizure control without producing drug-related undesirable effects that outweigh the desired therapeutic effects.
During the period 1989-2009, 14 new molecules with antiepileptic action have been developed. These second-generation AEDs comprise felbamate (FBM), gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), pregabalin (PGB), rufinamide (RUF), stiripentol (STP), tiagabine (TGB), topiramate (TPM), vigabatrin (GVG) and zonisamide (ZNS). Most recently, third-generation AEDs have been introduced, comprising eslicarbazepine acetate (ESL) and lacosamide (LCS).
Although newer AEDs have not demonstrated a superior efficacy compared with older molecules, most of them have been advertised as having a better tolerability profile, fewer drug interactions and simpler pharmacokinetics. [2, 3] However, our knowledge concerning their safety profiles is insufficient due to the limited number of patients exposed to them so far. [2, 3] Particularly in children, information on AED safety and tolerability is generally poor and is only acquired late, since approval for paediatric use is only granted with considerable delay, after promising results have been obtained in adults. Differences between children and adults in regard to drug safety and tolerability monitoring may be related to underreporting during off-label use [4] or underrecognition/ appreciation of adverse effects by caregivers. [5] Some adverse effects, especially those related to CNS toxicity, are particularly insidious in young children and in those with neurological comorbidities and psychiatric or behavioural problems. [6] A standardized adverse event questionnaire may be useful for monitoring adverse effects and optimizing AED therapy, [7] although data on subjective symptoms are hardly obtained from young children.
We performed a literature review with the aim of evaluating safety and tolerability of secondand third-generation AEDs in children. A PubMed search was conducted with the purpose of identifying English-language studies published between 1 January 1989 and 1 January 2011 that reported any adverse event having occurred in children with epilepsy in whom second-and third-generation AEDs were administered.
Criteria for Selection of Articles
For the review of safety and tolerability of the newer AEDs, we assessed available literature according to predefined criteria. We used the electronic database PubMed to identify articles published between 1 January 1989 and 1 January 2011 with the following limits: (i) age range between 0 and 18 years; and (ii) English language. The literature search identified all articles that included the terms 'epilepsy AND adverse effects AND eslicarbazepine OR felbamate OR gabapentin OR vigabatrin OR lacosamide OR levetiracetam OR lamotrigine OR oxcarbazepine OR pregabalin OR rufinamide OR stiripentol OR tiagabine OR topiramate OR zonisamide'. Studies including both children and adults were reviewed only if data on safety were reported separately for children. Since this review includes various adverse effects and several reports of single cases and small series, we chose to perform a descriptive analysis without pooling of data.
Data were reviewed for safety and tolerability information from 308 articles: 1 on ESL, 11 on FBM, 15 on GBP, 57 on GVG, 2 on LCS, 56 on LTG, 34 on LEV, 23 on OCX, 2 on PGB, 7 on RUF, 3 on STP, 16 on TGB, 55 on TPM and 26 on ZNS. The selection process of articles is reported in figure 1.
Safety and Tolerability: General Considerations
Optimal treatment of epilepsy first demands correct recognition of the types of seizures and correct diagnosis of the specific type of epilepsy or syndrome (table I) . Seizure aggravation as a consequence of prescribing an inappropriate AED for the particular seizure type or because of a paradoxical exacerbation of seizures should be followed by prompt review of treatment [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] (table II) . Once identified, the most appropriate AED, starting with low doses, slow titration, adequate posology choice and individualization of the minimal effective maintenance doses, may greatly improve safety and tolerability. [19] Most of the new AEDs are being used with the belief that monitoring of serum levels is unnecessary. Although monitoring of drug concentrations in the blood is not routinely indicated, some of the new AEDs exhibit such a wide interand intra-individual variability in absorption and kinetics that therapeutic monitoring is advised. [20] The strongest cases for routine therapeutic drug monitoring can be made for LTG, OXC, STP, TGB and ZNS, mainly due to inter-individual variation in metabolism and clearance. [20] Therapeutic drug monitoring has lower utility for GBP, PGB, GVG. [20] There are no generally accepted target ranges for most of the newer AEDs and a wide range in serum concentration has been associated with clinical efficacy. [21] Therefore, although routine monitoring cannot be recommended, it might still be useful to establish an individual reference level that helps avoid overtreatment and dosage adjustments in the presence of factors that might alter their pharmacokinetics. [22] Monitoring is also needed to assess compliance when breakthrough seizures occur, to substantiate clinically suspected toxicity, and drug interactions.
When prescribing a polytherapy, the clinician must be fully aware of the potential for pharmacokinetic and pharmacodynamic AED interactions that influence the risk of developing adverse Excluded (n = 718):
• no safety and tolerability information (n = 589) • adults (n = 98)
• literature reviews (n = 31) Excluded (n = 53 adults) effects. [23] The main pharmacokinetic interactions to consider in AED polytherapy are cytochrome P450 (CYP) metabolism competition and protein binding and displacement. Overall, newer AEDs have less potential for interactions due to minimal or null binding to blood albumin (e.g. ESL, FBM, GBP, LCS, LEV, RUF, TPM and GVG), and their primary renal excretion or metabolism by non-CYP enzymes or uridine glucoronyl transferases (e.g. GBP, LCS, LEV, RUF,TPM, GVG). [23, 24] Pharmacodynamic interactions can modify pharmacological effects and cause adverse effects, without changes in drug concentrations. In particular, the adverse effects of any drug can be increased by other drugs with similar properties. One example is the reciprocal potentiation of the neurotoxic effects when sodium channel-blocking AEDs are coadministered. [25, 26] One unsolved issue concerns the usefulness of laboratory monitoring for the early identification of subclinical allergic or cytotoxic idiosyncratic reactions in asymptomatic patients. Although routine blood and urine screening should be obtained at baseline, only on rare occasions do these BDZs = benzodiazepines; CBZ = carbamazepine; CLB = clobazam; ESM = ethosuximide; FBM = felbamate; GBP = gabapentin; GTCS = generalized tonic-clonic seizures; GVG = vigabatrin; IGE = idiopathic generalized epilepsy; LEV = levetiracetam; LTG = lamotrigine; OXC = oxcarbazepine; PB = phenobarbital; PHT = phenytoin; RUF = rufinamide; STP = stiripentol; TPM = topiramate; VPA = valproate; ZNS = zonisamide. BDZs = benzodiazepines; CBZ = carbamazepine; CSWS = continuous spikes and waves during slow sleep; GBP = gabapentin; GVG = vigabatrin; LTG = lamotrigine; OXC = oxcarbazepine; PB = phenobarbital; PHT = phenytoin; TGB = tiagabine.
results alert clinicians to the potential occurrence of severe adverse events. [27] Laboratory monitoring is necessary if the patient is presenting with abnormal signs which suggest serious adverse effects such as bruising, bleeding, rash, abdominal pain, vomiting, jaundice, sedation, lethargy, coma and deterioration in seizure control. [28] Regular clinical supervision, paying special attention to sedative adverse effects, is essential. The search for sedative adverse effects is especially difficult in infants or mentally impaired children [29] because marked cognitive and physical slowing may be erroneously attributed to seizures or to the causative disorder rather than to therapy. Slowing or worsening in school performance should always raise the possibility of an inappropriate choice of AED or an excessive dose.
Adverse Effects
Drug-induced adverse effects may be divided into two classes: 'dose-related or pharmacology-related' (Type A) and 'idiosyncratic' (Type B), although, at times, they do not necessarily fit either category.
Dose-Related Adverse Effects
Most dose-related adverse effects are generic and predictable, explained by the known pharmacological properties of the individual agent and usually observed at the beginning of treatment or following dosage increase (table III) . They are usually reversible upon dosage adjustment and rarely require discontinuation of therapy. In controlled trials of AEDs, where different doses are compared, most adverse effects are dose related. [35, 75, 76] Although information drawn from these studies may help choosing the daily doses that make adverse effects less likely, avoiding dose-related adverse effects may be very difficult as tolerance and adaptation to them vary widely among patients.
Risk Factors for Dose-Related Adverse Effects

Other Diseases Associated with Epilepsy
AEDs that are primarily metabolized in the liver, such as FBM, LTG and TGB, may rise to toxic levels in patients with liver disease. In these patients those drugs should not be considered as a first choice. If no alternatives exist, their use requires close monitoring of dosage. [71] To avoid dose-related adverse effects in patients with renal disease, AEDs with predominantly renal excretion, such as GBP and TPM, should be avoided or used at low dosage. [77] Children with refractory epilepsy who are co-treated with the ketogenic diet and carbonic anhydrase inhibitor AEDs, such as TPM and ZNS, are at risk for urolithiasis. [77] 
Starting Dose and Titration Rate
The frequency and severity of most doserelated adverse effects is crucially influenced by the starting dose and titration speed. [78, 79] For this reason, particularly in the paediatric setting, special care should be taken not to exceed the recommended initial dose and speed of titration. A slow titration may also minimize CNS adverse effects by allowing pharmacodynamic tolerance and early detection of subtle or prodromal signs, which can, in turn, indicate that adverse effects might worsen with further dose increase. [6] Doserelated adverse effects of AEDs may occur in individual patients even when AED levels are within the reference range. [22] This problem arises, in part, because a reference range is only a statistical estimate, applying to a population of patients, indicating a range in which a therapeutic response is likely to occur without toxicity. However, there are large inter-individual differences with regard to the blood level that will result in a therapeutic response or toxicity. [21] 
Associated Drugs
Dose-related adverse effects often increase when multiple AEDs are combined. Co-administration of two or more AEDs, or concomitant use of one or more drugs of a different class, also increase the potential toxicity of a given AED. [23, 24] 
Most Frequent Dose-Related Adverse Effects to Antiepileptic Drugs (AEDs)
The most commonly reported dose-related adverse effects in children are listed in table III, according to the involved anatomo-physiological systems (CNS, gastrointestinal system, skin and renal system). No rating order of frequency is + [32] + [33] + [34] + [35] + [36, 37] + [38] Insomnia + [39] + [40] + [41] [42] [43] Somnolence + [39] + [30, 31] + [40] + [32] + [33, 44, 45] + [46] + [34, 47, 48] + [41] [42] [43] + [35] + [36, 49] + [50] Sedation + [51] Concentration problems + [36] Aphasia/dysarthria
+ [52] Depression + [31] + [53] + [52, 54] Suicidal ideation + [53] Behavioural problems + [39, 55] + [30, 56] + [51, 57] + [40] + [32, 58] + [59, 60] + [45] + [46] + [41] [42] [43] + [35] + [36, 37, 49, 52] + [38, 50] Hallucinations/psychosis + [57] + [58] + [61] + [52] Ataxia + [31] + [62] + [44] + [41] [42] [43] + [52] Tremor + [62] + [42] Dizziness + [62] + [33, 44] + [46] + [34, 48] + [35] + [37] Blurred vision/visual field deficits + [51, 63] + [53] Diplopia/eye movement abnormalities
+ [59, 62] + [44] + [34, 48] + [41] Dyskinesia/choreoathetosis Myoclonus + [64] + [59, 65] Tics + [53] + [66] Paraesthesia + [37] Headache + [32] + [33, 44] + [47, 48] + [41] + [36, 49, 52] + [50] Constipation + [38, 50] Diarrhoea + [52] + [50] Abdominal pain
+ [50] Nausea + [51] + [53] + [62] + [44] + [34, 47] + [41] [42] [43] + [37] + [38] Vomiting + [39] + [32] + [44] + [34, 47, 48] + [41, 42] + [50] Continued next page possible as the number of studies for each drug is widely variable.
[ 70, [72] [73] [74] 
Idiosyncratic Adverse Effects
Idiosyncratic adverse effects (Type B) occur sporadically and unpredictably in susceptible individuals only, and irrespective of dosage. Their pathogenesis is apparently unrelated to the known mechanisms of action of the offending drug, but rather represents the consequence of an abnormal, often immunological, reaction. [80] Considering the heterogeneity of the clinical presentations and the different properties of the causative agents, it is not surprising that idiosyncratic reactions involve a broad range of mechanisms and that more than one mechanism be involved for a single event. Schematically, the main pathogenetic mechanisms include:
Direct cytotoxicity: The idiosyncratic reaction is caused by a direct cytotoxic effect of the drug or its metabolites, without pathogenetic involvement of the immune system. [81] The best example of such reactions is probably valproate (VPA)-induced hepatotoxicity. There is experimental and clinical evidence for a direct cytotoxic effect of two VPA metabolites, namely 4-en VPA and its b-oxidation derivative 2,4-dien VPA. [82] It has been shown that 2,4-diene-VPA is a reactive species capable of causing inhibition of b-oxidation and mitochondrial dysfunction. [83] Since the formation of 4-en-VPA is largely catalyzed by CYP2C9, whose activity is inducible and higher in infants co-medicated with enzyme-inducing AEDs, this finding may explain why the risk of VPA-induced liver toxicity is highest in infants who are co-medicated with enzyme-inducing AEDs. [84] Immune-mediated hypersensitivity reactions: These reactions involve abnormal humoral-or cell-mediated responses. AEDs may initiate these responses by interacting with cells of adaptive immunity. In this case, the drug, or a metabolite, needs to act as a hapten, i.e. it has to covalently bind and modify a macromolecule to become immunogenic. [85] Alternatively, electrophilic metabolites can react with nucleophilic groups on proteins without covalent binding. [86] The drug-peptide + [50] Haematological abnormalities + [40] MRI abnormalities + [72] [73] [74] a The list is assembled by anatomophysiological systems (CNS, gastrointestinal system, skin, and renal system). complex, which is recognized as foreign, is thus processed by antigen presenting cells that can, in turn, trigger B-or T-cell-mediated responses. The so called 'danger hypothesis' [87, 88] has been formulated to explain both the low incidence of hypersensitivity reactions in patients treated with such drugs, as well as the increased risk of developing them during viral infections, surgery and radiation therapy. In accordance with this hypothesis, inflammatory signals derived from cells that have been damaged, act on antigen presenting cells and T cells to trigger an immune-mediated reaction. [80] Reactive drug metabolites are often the causative agents also in the case of immunemediated reactions as they may bind covalently to macromolecules and trigger an immune response. [89] For instance, LTG, is mostly cleared by glucuronide conjugation and only minor amounts are converted by CYP enzymes to an arene oxide intermediate. Since VPA inhibits LTG glucuronidation, in patients co-medicated with VPA a higher percentage of the LTG dose is converted through the alternative CYP-mediated pathway to the oxide intermediate, which may explain the greater susceptibility of these patients to LTGinduced skin rashes. [89] Children are at higher risk of LTG-induced idiosyncratic reactions because their CYP enzymatic system is faster and glucuronide conjugation slower compared with adults. [83] [84] [85] [86] [87] [88] [89] [90] Considerable evidence indicates that FBM-induced liver and bone marrow toxicity is mediated by the reactive metabolite atropaldehyde. [91, 92] Both atropaldehyde and another FBM metabolite, alcohol carbamate, have been shown to inhibit glutathione transferase and cause cytotoxicity in human hepatocytes. [93] Likewise, FBM metabolites form covalent adducts with human serum albumin. [94] Since the half-life of the atropaldehyde precursors CPPA (3-carbamoyl-2-phenylpropionic acid) and 4-hydroxy-5-phenyl-(1,3)-oxazinan-2-one is in the order of hours, it has been suggested that these FBM metabolites may travel from the liver and release atropaldehyde to other sites such as the bone marrow. [93, 94] Whether immune mechanisms play an important role in the toxicity of FBM metabolites is unclear, but their involvement is suggested by experimental studies on the immunogenic potential of reactive FBM metabolites [95] and the observation that patients with a history of hypersensitivity reactions and autoimmune disease are at greater risk of developing FBM-induced aplastic anaemia. [96] Off-target pharmacology: These reactions occur when a drug interacts directly with a system other than that for which it is intended. [97] Examples include some unusual CNS adverse effects such as Parkinsonian symptoms [98] or cognitive deterioration [99] with VPA, and dyskinesia with FBM. [64] 
Risk Factors for Idiosyncratic Adverse Effects
Genetically-Determined Predisposition
Identical twins may experience similar idiosyncratic reactions.
[100] Also siblings of patients who had immune-mediated idiosyncratic reactions to an aromatic AED such as phenytoin (PHT), carbamazepine (CBZ), phenobarbital (PB) and primidone (PRI) are at greater risk. [101] The US FDA has recently made a labelling change to the drug information concerning CBZ in which it is recommended that before starting treatment with the drug all Asians be genotyped for the HLA-B*1502 allele. [102] Recent data implicate this allele as a marker for CBZ-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Han Chinese. [103] 
Age
Children are more predisposed to idiosyncratic drug reactions than adults. For example, the incidence of SJS in children started on LTG has been estimated to be as high as 1 : 100 compared with 1 : 1000 in adults. [79] Young age is also a major risk factor for VPA-induced toxic hepatitis, for which the highest risk is in infants younger than 2 years of age. [104] The reasons for the increased risk of idiosyncratic drug reactions in infancy might be due to age-related differences in drug metabolism. [105] In young infants, CYPmediated reactions are faster and glucuronide conjugation is reduced with respect to adults and this may lead to increased production of reactive metabolites. [83] 
Other Diseases Associated with Epilepsy
Concomitant diseases play an important role in the pathogenesis of several cytotoxic or allergic idiosyncratic adverse effects. Rheumatoid arthritis, systemic lupus erythematous, Hashimoto thyroiditis, panhypogammaglobulinemia, idiopathic thrombocytopenic purpura, high serum antinuclear antibody concentrations and a history of cytopenia or hypersensitivity to other AEDs are risk factors for FBM-induced aplastic anaemia. [80] Hypersensitivity reactions to aromatic AEDs are more frequently observed in patients with other immune system disorders, systemic lupus erythematous, infectious diseases and in those who are under treatment with corticosteroids. VPA-induced liver toxicity is another example of an idiosyncratic adverse effect that is strongly influenced by concomitant conditions. Several metabolic disorders, including urea cycle defects, organic acidurias, multiple carboxylase deficiency, mitochondrial or respiratory chain dysfunction, cytochrome aa3 deficiency in muscle, pyruvate carboxylase deficiency and pyruvate dehydrogenase complex deficiency all predispose to VPA-induced hepatotoxicity. [80] Patients with GM1 gangliosidosis type 2, spinocerebellar degeneration, Friedreich ataxia, Lafora body disease and Alpers-Huttenlocher disease are also more susceptible to VPA-induced hepatotoxicity. [106] 
Associated Drugs
Associated drugs may strongly influence susceptibility to idiosyncratic adverse reactions. For example, enzyme-inducing AEDs increase the incidence of VPA-induced liver toxicity, pancreatitis, hyperammonemia and encephalopathy. [107] Concomitant treatment with VPA increases the risk of LTG-induced hypersensitivity. [80] 
History of Previous Allergic Drug Reactions
Risk of having a further rash when initiating a new drug is generally increased in a patient who has already had a previous drug-induced rash. Cross-sensitivity among aromatic AEDs occurs in about half of patients. [108] In particular, caution should be taken when prescribing LTG and OXC in patients with a history of rash to another AED or non-AED medication. [108] 
Starting Dose and Titration Rate
The risk of allergic reactions is greatly increased when treatment is started at high doses, rapidly increased, or both, possibly because slow titration may allow desensitization to occur. [19] A relationship between starting dose, titration rate and the incidence of cutaneous reactions is particularly obvious for LTG. [79] 
Most Frequent Idiosyncratic Adverse Effects to AEDs
Due to their clinical relevance, idiosyncratic adverse effects of older AEDs are also considered (table IV) .
Cutaneous manifestations are the most common idiosyncratic reactions caused by AEDs. The severity ranges from very benign mild skin rashes, which are usually morbilliform or maculopapular and occur shortly after starting therapy, to potentially life-threatening dermatological diseases such as rash with eosinophilia and systemic symptoms (DRESS), SJS and TEN (Lyell's syndrome).
DRESS, which is also named anticonvulsant hypersensitivity syndrome, is characterized by fever, skin eruption, eosinophilia, atypical lymphocytosis, arthralgia, lymphadenopathy and multi-organ involvement [109] and is observed most frequently with the aromatic AEDs PHT and CBZ, with incidences of about 1-5 cases per 10 000 exposures.
In an analysis from the International Case Control Study on Severe Cutaneous Adverse Reactions (1989) (1990) (1991) (1992) (1993) (1994) (1995) , 21% of the SJS and TEN cases reported intake of an AED. [110] The risk of developing SJS and TEN was greatest in the first 8 weeks following onset of treatment. The risk of SJS and TEN was highest with CBZ, PB and PTH therapy. SJS and TEN may present as a febrile illness unexplained by an infections illness. Patients might experience symptoms resembling an upper respiratory tract infection, which precede the mucocutaneous lesions of SJS and TEN by 1-3 days. A skin detachment of less than 10% defines SJS, while a detachment that is more than 30% defines TEN. Ocular sequelae, including longterm conjunctivitis and blindness, may follow the acute phase in up to 35% of TEN patients and a smaller percentage of those with SJS. [111, 112] About 5% of patients with SJS and 30% of patients with TEN die from their disease. [111, 113] Bacterial infection and respiratory illness are often responsible for mortality resulting from SJS or TEN. [114, 115] Aplastic anaemia is the most frequent and serious haematological reaction reported with AEDs. FBM is by far the AED with the highest potential for causing this complication with a risk rate of 1 in 5000-10 000. [116] The incidence of CBZ-induced aplastic anaemia is between 1 : 50 000 and 1 : 200 000 exposed patients. [117] More rarely, selective suppression of bone marrow cells may also lead to agranulocytosis and pure cell aplasia.
Sporadic cases of thrombocytopenia, probably immune-mediated, have been described. [117] Hepatotoxicity is frequently observed in patients with idiosyncratic adverse reactions because liver is the primary organ responsible for drug metabolism and, therefore, more exposed to reactive metabolites. Hepatitis may be one of the symptoms of DRESS or occur in isolation, especially if caused by immune-mediated mechanisms or direct cytotoxic damage. [118] Pancreatitis is a rare complication of VPA therapy with a mortality rate that has been estimated at 21%. [119] Several idiosyncratic adverse effects caused by the phenomenon of off-target pharmacology involve CNS. Some examples are VPA-induced encephalopathy [99, 120] and PHT-induced dyskinesia. [121] Other systems or organs can also be involved. Acute secondary angle-closure glaucoma, acute bilateral myopia and suprachoroidal effusion are ocular reactions induced by TPM. [122] Another example is VPA-induced Fanconi's syndrome. [123] 
Cognitive Adverse Effects and Long-Term Safety
While adverse effects that are circumscribed and have clear onset are relatively easy to identify, toxicities that emerge insidiously (e.g. progressive cognitive slowing) may escape detection or their drug-induced determinism may remain obscure. There is no standardized definition of what constitutes 'long-term' safety or tolerability; this terminology is used in the literature referring to periods of at least 6 months to many years. Furthermore, there are no standardized instruments used in clinical practice for assessing drugassociated adverse effects.
Cognitive impairment, which often occurs in children with epilepsy, is in part attributed to AEDs. [6] Since AEDs exert their antiepileptic properties mainly by modulating ion channels, neurotransmitters and second messengers, they can sometimes interfere with brain pathways involved in learning, memory and emotional behaviour. Special attention should be given to CNS adverse effects that involve cognition, thought processes, memory, speech, coordination and gait, as well as the appearance of lethargy, emotional and behavioural reactions, psychotic or depressive symptoms or suicidal behaviour/ideation. Although a detrimental dose-dependent effect of some AEDs on cognition is self-evident, only a few controlled studies have addressed this point in children. [124] Clear evidence has been obtained about the reduction of intelligence quotient scores and increased P300 wave latency, an electrophysiological marker of reduced speed in cognitive processing, in children treated with PB. [125] The long-term cognitive effects of newer AEDs in children are largely unknown. [6] Few well designed studies have systematically investigated the cognitive effects of newer AEDs in children and adolescents in the short term. Open-label studies indicate that OXC monotherapy had no impact on cognitive function and intelligence over 6 months in children and adolescents with newly diagnosed partial-onset seizures, [126] whereas the cognitive effects of TPM over 28 weeks were slightly worse than those of CBZ in children with benign rolandic epilepsy. [127] A retrospective analysis of long-term use of LEV and TPM showed that cognitive adverse effects in children and adults with epilepsy were more common with TPM than with LEV and more frequently led to drug withdrawal. [128] Amongst children and adults treated with LEV, a minority can develop acute psychosis consisting of visual or auditory hallucinations and delirium within the first few weeks of treatment. [129] A previous history of mental illness greatly increases the risk for psychotic symptoms. This adverse effect responds promptly to drug withdrawal or reduction. [129] The report of irreversible concentric visual field defect in 30-50% of patients of all ages treated with GVG [51, 63] implies that there is a need for careful evaluation of the risk versus benefit issues before it is prescribed. This is a point of major concern since GVG is effective, and well tolerated, in the treatment of infantile spasms but the visual defect is asymptomatic and indefinable in the infantile spasms age group. It is still unclear if GVG-related visual field defects may represent an idiosyncratic adverse effect [130] rather than result from dose-dependent toxicity. [63] Its exact pathophysiological mechanisms remain unclear, but the site of toxicity could be the inner layer of retina, where GVG causes irreversible inhibition of GABA aminotransferase. [131] A mild defect could be of very little clinical significance, especially in children with severe developmental disabilities. The relationship between duration of exposure to the drug and development of visual field defect has not yet been exactly established. Although a correlation with total GVG load seems to exist, [63] a dose-dependent mechanism has been questioned. [130] As most responses to GVG treatment are obtained within the initial 3 weeks, non-responders will have little risk, if any, of developing a visual field defect if the drug is promptly withdrawn. In responders, it has been suggested that GVG be discontinued after about 6 months. [132] Nousiainen et al. [133] (2001) found that after GVG withdrawal no significant recovery was observed in visual field but, conversely, no progression was found with continued therapy. Whether to switch to an alternative treatment or to no treatment should be planned according to the individual clinical and EEG characteristics. Symmetric magnetic resonance imaging (MRI) hyperintensities (T2 and DWI sequences) and magnetic resonance spectroscopy (MRS) abnormalities have been described in the globus pallidi, thalami, dentate nuclei and cerebral peduncles of patients with infantile spasms treated with GVG. [72] [73] [74] MRI abnormalities, which are supposed to depend on both high GVG dosage and younger age, are transient and disappear after GVG withdrawal. [72, 73] MRS changes, in contrast, persist after GVG discontinuation; this might indicate that these changes are related to seizure activity rather than a direct drug effect. [74] However, the potential pathogenic mechanisms remain unclear.
Conclusions
Preventing and managing adverse effects during AED therapy is a major challenge. Strategies for reducing common dose-related adverse effects include optimal AED selection, slow titration and reduction of co-therapy, leaving the patient on monotherapy whenever feasible. Idiosyncratic adverse effects cannot be reliably predicted based on currently available knowledge, but careful history taking and clinical observation can help with reducing their frequency and limiting their severity. In addition to the considerations that apply to all ages, it is important for clinicians to be aware of the differences between adults and children with regard to the nature and frequency of AED adverse effects, so that these can be avoided or at least minimized in younger patients.
